Can itraconazole oral capsules cause acute kidney injury after a single dose in an otherwise healthy adult?

Itraconazole and Acute Kidney Injury After Single Dose

Itraconazole oral capsules are extremely unlikely to cause acute kidney injury after a single dose in an otherwise healthy adult. The drug is primarily hepatically metabolized with minimal renal excretion (<1% of unchanged drug), and AKI from itraconazole typically occurs only in specific high-risk contexts involving drug interactions or prolonged exposure 1.

Pharmacokinetic Evidence Against Single-Dose AKI Risk

The FDA labeling data clearly demonstrates that itraconazole is not directly nephrotoxic through its primary pharmacokinetic pathways:

• Renal excretion of unchanged itraconazole accounts for less than 1% of an administered dose 1
• The drug is extensively metabolized by the liver via CYP3A4, not eliminated by the kidneys 1
• Itraconazole distributes widely into tissues (>700 L volume of distribution) with concentrations in kidney 2-3 times higher than plasma, but this tissue distribution does not translate to direct nephrotoxicity 1

When AKI Actually Occurs With Itraconazole

The documented cases of itraconazole-associated AKI involve specific high-risk scenarios, not single-dose exposure:

Drug Interaction-Mediated AKI

The primary mechanism is rhabdomyolysis from drug interactions, particularly:

• Concurrent statin use (especially simvastatin) where itraconazole inhibits CYP3A4 metabolism of statins, leading to myopathy, rhabdomyolysis, and secondary AKI 2, 3
• Immunosuppressant combinations (cyclosporine + statin + itraconazole) creating multiplicative risk 3

These cases required at least 8 days of itraconazole therapy before symptom onset 2, not single doses.

Long-Term Exposure Risks

A recent 2025 study of histoplasmosis patients on long-term itraconazole showed:

• Side effects occurred in 27.8% of patients, but median time to any side effect was 45 days 4
• Direct nephrotoxicity was not among the commonly reported side effects (hepatotoxicity, GI symptoms were most common) 4

Guideline Context for Nephrotoxic Drug Management

The KDIGO guidelines on drug-associated AKI emphasize that 5, 6:

• Potentially nephrotoxic agents should not be withheld in life-threatening conditions due to AKI concerns 5
• Drug-associated kidney injury typically requires either sustained hemodynamic effects or direct tubular toxicity—neither of which occurs with single-dose itraconazole 5
• Monitoring is recommended for drugs "associated with kidney injury," but this applies to chronic or repeated exposure, not single doses 6

Critical Caveats

The only scenario where single-dose concern is warranted:

1. Pre-existing severe renal impairment: While itraconazole exposure is actually reduced by 30-40% in moderate-severe renal impairment 1, patients with CrCl <20 mL/min on concurrent nephrotoxic medications warrant closer monitoring
2. Concurrent high-risk drug combinations: If the patient is already on statins, ACE inhibitors/ARBs, or other CYP3A4 substrates, even a single dose could theoretically initiate interactions—though clinical AKI still requires time to develop

Bottom Line

In an otherwise healthy adult without drug interactions or pre-existing renal disease, a single dose of itraconazole will not cause AKI. The drug's hepatic metabolism, minimal renal excretion, and documented safety profile in single-dose pharmacokinetic studies 1 support this conclusion. If AKI develops temporally associated with itraconazole initiation, investigate alternative causes (volume depletion, other nephrotoxins, drug interactions) rather than attributing it to the itraconazole itself 5, 6.